XML 52 R42.htm IDEA: XBRL DOCUMENT
v3.25.3

Significant Agreements - Bristol Myers Squibb Collaboration Agreement (Details) - USD ($) $ / shares in Units, $ in Thousands |  |  |  |  | 3 Months Ended | 9 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | --- | ---
May 24, 2024 | Jul. 05, 2023 | Jul. 30, 2021 | Mar. 20, 2018 | Sep. 30, 2025 | Sep. 30, 2024 | Sep. 30, 2025 | Sep. 30, 2024 | Jun. 30, 2025 | Dec. 31, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Deferred revenue, current |  |  |  |  | $ 2,685 |  | $ 2,685 |  |  | $ 8,850
Collaboration revenue |  |  |  |  | 2,415 | $ 970 | 9,663 | $ 133,034 |  |
Deferred revenue, non-current |  |  |  |  | 0 |  | 0 |  |  | 3,448
Collaboration Program, US Rights | Minimum |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Collaboration Agreement, Expected Allocation of initial Transaction Price |  |  |  | $ 15,000 |  |  |  |  |  |
Collaboration Program, US Rights | Maximum |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Collaboration Agreement, Expected Allocation of initial Transaction Price |  |  |  | 25,000 |  |  |  |  |  |
Collaboration Program, Global Rights |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Collaboration Agreement, Potential Regulatory Milestone Payments per Program |  |  |  | 187,500 |  |  |  |  |  |
Collaboration Agreement, Potential Commercial Sale Milestone Payments |  |  |  | 375,000 |  |  |  |  |  |
Collaboration Program, Global Rights | Minimum |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Collaboration Agreement, Expected Allocation of initial Transaction Price |  |  |  | 10,000 |  |  |  |  |  |
Collaboration Program, Global Rights | Maximum |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Collaboration Agreement, Expected Allocation of initial Transaction Price |  |  |  | 18,000 |  |  |  |  |  |
Collaboration revenue |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Collaboration revenue |  |  |  |  | 2,415 | 970 | 9,613 | 132,984 |  |
Bristol Myers Squibb |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Collaboration Agreement, Potential Regulatory and Commercial Milestone Payments per Program |  |  |  | 562,500 |  |  |  |  |  |
Collaboration revenue |  |  |  |  | 2,400 | $ 1,000 | 9,600 | $ 133,000 |  |
Deferred Revenue |  |  |  |  | 2,700 |  | 2,700 |  | $ 5,100 |
Bristol Myers Squibb | Collaboration Program, US Rights |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Collaboration Agreement, Exercise fee per Program |  |  |  | 80,000 |  |  |  |  |  |
Bristol Myers Squibb | Collaboration Program, Global Rights |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Collaboration Agreement, Exercise fee per Program |  |  |  | 55,000 |  |  |  |  |  |
Bristol Myers Squibb | Collaboration Program, US, tau/ BMS-986446 |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Collaboration Program, US License Agreement, Upfront Payment |  |  | $ 80,000 |  |  |  |  |  |  |
Bristol Myers Squibb | Collaboration Program, Global, tau/ BMS-986446 |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Collaboration Agreement, Potential Regulatory and Commercial Milestone Payments per Program |  | $ 562,500 |  |  |  |  |  |  |  |
Collaboration Agreement, Allocation of Initial Transaction Price |  | 17,900 |  |  |  |  |  |  |  |
Collaboration program, Global Exercise Fee |  | 55,000 |  |  |  |  |  |  |  |
Collaboration Agreement, Total Transaction Price, PRX005 Global |  | $ 72,900 |  |  |  |  |  |  |  |
Bristol Myers Squibb | Collaboration Program, Global, PRX019 |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Collaboration Agreement, Potential Commercial Sale Milestone Payments | $ 375,000 |  |  |  |  |  |  |  |  |
Collaboration revenue |  |  |  |  | 2,400 |  |  |  |  |
Collaboration Agreement, Allocation of Initial Transaction Price |  |  |  | 17,400 |  |  |  |  |  |
Allocated consideration to performance obligations | 106,300 |  |  |  |  |  |  |  |  |
Collaboration program, Global Exercise Fee | 80,000 |  |  |  |  |  |  |  |  |
Collaboration Agreement, Potential Development and Regulatory Milestone Payments | $ 242,500 |  |  |  |  |  |  |  |  |
BMS (formerly Celgene) |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Collaboration Agreement, Upfront Payment |  |  |  | $ 100,000 |  |  |  |  |  |
Collaboration Agreement, Option fees and Milestone payments, Payment Term |  |  |  | 30 days |  |  |  |  |  |
BMS (formerly Celgene) | Private Placement |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Share Subscription Agreement, Number of ordinary shares issued in transaction (in shares) |  |  |  | 1,174,536 |  |  |  |  |  |
Share Subscription Agreement, Price per share (in dollars per share) |  |  |  | $ 42.57 |  |  |  |  |  |
Share Subscription Agreement, Consideration received on transaction |  |  |  | $ 50,000 |  |  |  |  |  |
Share Subscription Agreement, Premium received on transaction |  |  |  | 10,200 |  |  |  |  |  |
Collaborative Arrangement | Bristol Myers Squibb |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Accounts receivable |  |  |  |  | 0 |  | 0 |  |  | $ 0
Revenue, Remaining performance obligation, Amount |  |  |  |  | $ 2,700 |  | $ 2,700 |  |  |
Collaborative Arrangement | BMS (formerly Celgene) |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Collaboration Agreement, Initial Transaction Price |  |  |  | $ 110,200 |  |  |  |  |  |

X
- Definition Revenue, Performance Obligation, Allocated Consideration ( Amount of Transaction Price Allocated to each Performance Obligation) + References No definition available. + Details
Name: | prta_AllocatedConsiderationtoPerformanceObligations
Namespace Prefix: | prta_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaboration Agreement, Allocation of Initial Transaction Price + References No definition available. + Details
Name: | prta_CollaborationAgreementAllocationOfInitialTransactionPrice
Namespace Prefix: | prta_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaboration Agreement, Exercise Fee (US Rights) per Program + References No definition available. + Details
Name: | prta_CollaborationAgreementExerciseFeeUSRightsPerProgram
Namespace Prefix: | prta_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaboration Agreement, Expected Allocation of Initial Transaction Price + References No definition available. + Details
Name: | prta_CollaborationAgreementExpectedAllocationofInitialTransactionPrice
Namespace Prefix: | prta_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaboration Agreement, Option Fees and Milestone Payments, Payment Term + References No definition available. + Details
Name: | prta_CollaborationAgreementOptionFeesandMilestonePaymentsPaymentTerm
Namespace Prefix: | prta_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaboration Agreement, Potential Commercial Milestone Payments Per Program + References No definition available. + Details
Name: | prta_CollaborationAgreementPotentialCommercialMilestonePaymentsPerProgram
Namespace Prefix: | prta_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaboration Agreement, Potential Development and Regulatory Milestone Payments + References No definition available. + Details
Name: | prta_CollaborationAgreementPotentialDevelopmentAndRegulatoryMilestonePayments
Namespace Prefix: | prta_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaboration Agreement, Potential Regulatory Milestone Payments Per Program + References No definition available. + Details
Name: | prta_CollaborationAgreementPotentialRegulatoryMilestonePaymentsPerProgram
Namespace Prefix: | prta_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaboration Agreement, Potential Regulatory and Commercial Milestone Payments Per Program + References No definition available. + Details
Name: | prta_CollaborationAgreementPotentialRegulatoryandCommercialMilestonePaymentsPerProgram
Namespace Prefix: | prta_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaboration Agreement, Total Transaction Price, tau/BMS-986446 Global + References No definition available. + Details
Name: | prta_CollaborationAgreementTotalTransactionPriceTauBMS986446Global
Namespace Prefix: | prta_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaboration Agreement, Upfront Payment + References No definition available. + Details
Name: | prta_CollaborationAgreementUpfrontPayment
Namespace Prefix: | prta_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaboration Program, Option Exercise Fee + References No definition available. + Details
Name: | prta_CollaborationProgramOptionExerciseFee
Namespace Prefix: | prta_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Collaboration Program, US License Agreement, Upfront Payment + References No definition available. + Details
Name: | prta_CollaborationProgramUSLicenseAgreementUpfrontPayment
Namespace Prefix: | prta_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenue from Contract with Customers, Initial Transaction Price + References No definition available. + Details
Name: | prta_InitialTransactionPrice
Namespace Prefix: | prta_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Sale of Stock, Premium Received on Transaction + References No definition available. + Details
Name: | prta_SaleofStockPremiumReceivedonTransaction
Namespace Prefix: | prta_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details
Name: | us-gaap_AccountsReceivableNetCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_DeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_DeferredRevenueCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_DeferredRevenueNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of transaction price allocated to performance obligation that has not been recognized as revenue. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Cash received on stock transaction after deduction of issuance costs. + References No definition available. + Details
Name: | us-gaap_SaleOfStockConsiderationReceivedOnTransaction
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + References No definition available. + Details
Name: | us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + References No definition available. + Details
Name: | us-gaap_SaleOfStockPricePerShare
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | srt_ProductOrServiceAxis=prta_CollaborationProgramUSRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=prta_CollaborationProgramGlobalRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=prta_CollaborationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=prta_BristolMyersSquibbMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=prta_CollaborationProgramUSTauBMS986446Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=prta_CollaborationProgramGlobalTauBMS986446Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=prta_CollaborationProgramGlobalPRX019Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=prta_BMSFormerlyCelgeneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |